Wall Street analysts predict that Celsion Co. (NASDAQ:CLSN) will report earnings per share (EPS) of ($0.31) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Celsion’s earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.32). Celsion posted earnings of ($1.96) per share during the same quarter last year, which suggests a positive year over year growth rate of 84.2%. The company is expected to announce its next quarterly earnings results on Thursday, March 15th.
On average, analysts expect that Celsion will report full-year earnings of ($2.46) per share for the current financial year. For the next financial year, analysts forecast that the business will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.21) to ($1.08). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Celsion.
CLSN has been the topic of a number of research reports. Maxim Group upgraded Celsion from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Wednesday, October 4th. Zacks Investment Research upgraded Celsion from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Tuesday, August 29th. Oppenheimer initiated coverage on Celsion in a research note on Tuesday, November 21st. They set an “outperform” rating and a $9.00 price target on the stock. Finally, ValuEngine upgraded Celsion from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $11.90.
An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC acquired a new position in shares of Celsion Co. (NASDAQ:CLSN) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 3.97% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/25/brokerages-anticipate-celsion-co-clsn-to-post-0-31-eps.html.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.